Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.89	2.33	18.74	0	0
Revenue Growth (YoY)	-61.96%	-87.57%	-	-	-
Gross Profit	0.89	2.33	18.74	0	0
Selling, General & Admin	39.95	28.53	27.32	21.84	15.73
Research & Development	89.5	58.58	57.07	59.64	64.6
Other Operating Expenses	113.74	0	0	0	0
Operating Expenses	243.19	87.11	84.39	81.48	80.33
Operating Income	-242.3	-84.78	-65.65	-81.48	-80.33
Other Expense / Income	96.51	-0.83	0.01	-0.59	-2.08
Pretax Income	-338.82	-83.95	-65.66	-80.89	-78.25
Income Tax	-0.03	-0.14	0.14	0	0
Net Income	-338.79	-83.82	-65.8	-80.89	-78.25
Shares Outstanding (Basic)	7	3	3	2	1
Shares Outstanding (Diluted)	7	3	3	2	1
Shares Change	104.59%	28.19%	23.18%	67.05%	53.44%
EPS (Basic)	-49.12	-24.86	-25.02	-38.00	-61.25
EPS (Diluted)	-49.12	-24.86	-25.02	-38.00	-61.25
Free Cash Flow	-99.44	-80.18	-54.29	-80.06	-67.18
Free Cash Flow Per Share	-14.42	-23.78	-20.64	-37.50	-52.57
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-27347.97%	-3640.23%	-350.33%	-	-
Profit Margin	-38238.15%	-3598.75%	-351.14%	-	-
Free Cash Flow Margin	-11222.91%	-3442.77%	-289.71%	-	-
EBITDA	-337.85	-81.99	-63.66	-79.27	-77.35
EBITDA Margin	-38132.28%	-3520.27%	-339.71%	-	-
Depreciation & Amortization	0.96	1.96	2	1.62	0.9
EBIT	-338.82	-83.95	-65.66	-80.89	-78.25
EBIT Margin	-38241.08%	-3604.59%	-350.39%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).